Tell us about your practice:
Supporting Persistence Beyond the Injection.
Studies indicate that 50% of U.S. patients remain on LAI therapy for 6.5 months.*
Advantage data demonstrates a median duration of 9 months, an increase of 2.5 months (42%).
Let Advantage help you drive lasting adherence across your LAI patient population
Advantage helps remove barriers to care, fill treatment gaps, and support ongoing connection to LAI therapy.
